Estimating severe acute respiratory coronavirus virus 2 (SARS-CoV-2) seroprevalence from residual clinical blood samples, January–March 2021

We describe severe acute respiratory coronavirus virus 2 (SARS-CoV-2) IgG seroprevalence and antigenemia among patients at a medical center in January–March 2021 using residual clinical blood samples. The overall seroprevalences were 17% by infection and 16% by vaccination. Spent or residual samples...

Descripción completa

Detalles Bibliográficos
Autores principales: Graciaa, Daniel S., Verkerke, Hans P., Guarner, Jeannette, Moldoveanu, Ana Maria, Cheedarla, Narayanaiah, Arthur, Connie M., Maier, Cheryl L., Neish, Andrew, Auld, Sara C., Campbell, Angie, Gandhi, Neel R., Roback, John D., Shah, N. Sarita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2022
Materias:
Concise Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9726492/
https://www.ncbi.nlm.nih.gov/pubmed/36483398
http://dx.doi.org/10.1017/ash.2022.298

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9726492/
https://www.ncbi.nlm.nih.gov/pubmed/36483398
http://dx.doi.org/10.1017/ash.2022.298

Ejemplares similares